Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors

NCT01378377 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01378377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01378377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors
Lead sponsor
EMD Serono
Phase
Phase 1
Overall status
Terminated
Start date
May 27, 2011
Completion date
February 23, 2012
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor